Acral malignant melanoma in pregnancy: a case report
DOI:
https://doi.org/10.32385/rpmgf.v41i1.13960Keywords:
Malignant melanoma, PregnancyAbstract
The incidence of malignant melanoma is increasing dramatically, being one of the most common neoplasms during pregnancy and with high metastatic potential. Most develop in pre-existing pigmented nevi and the hyperpigmentation of pregnancy contributes to delayed diagnosis. Depths greater than one millimeter, ulceration and/or mitosis, and metastasis are associated with poor prognosis. Metastasis to the placenta and fetus is extremely rare. This clinical case selection aimed to raise awareness of the importance of identifying suspicious skin lesions early. The case concerns a 33-year-old pregnant woman, at 36 weeks of gestation, who went to the Family Health Unit due to an ulcerated lesion, difficult to heal, on the first toe of the left foot, with a gradual evolution of six months, which she associated with local trauma. On objective examination, it was observed a pigmented lesion of three centimeters, with irregular borders and heterogeneous coloration, and with a pericentimetric focal area of ulceration. Due to clinical suspicion of malignant melanoma, an urgent hospital consultation for teledermatological screening was requested. During the consultation, incisional skin biopsy and inguinal ultrasonography with cytopuncture of suspicious adenomegaly were performed. The patient underwent disarticulation of the first toe of the left foot and left inguinal dissection, which revealed a seven-millimeter thick acrolentiginous melanoma and micrometastases in two lymph nodes. The remaining imaging study did not show other secondary lesions. It was established the diagnosis of malignant melanoma classified as pT4bN2bM0, stage IIIC, with an indication for adjuvant immunotherapy, but poor prognosis. Thus, the case described emphasizes the importance of instilling our pregnant women (and others) to perform regular skin self-examination. It is up to us to carry out a thorough skin examination, especially in the presence of multiple pigmented nevi, allowing for timely detection, referral, and diagnosis and, therefore, access to potentially curative therapies.
Downloads
References
1. Still R, Brennecke S. Melanoma in pregnancy. Obstet Med. 2017;10(3):107-12.
2. Byrom L, Olsen C, Knight L, Khosrotehrani K, Green AC. Increased mortality for pregnancy-associated melanoma: systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29(8):1457-66.
3. Driscoll MS, Martires K, Bieber AK, Pomeranz MK, Grant-Kels JM, Stein JA. Pregnancy and melanoma. J Am Acad Dermatol. 2016;75(4):669-78.
4. Mendizábal E, De León-Luis J, Gómez-Hidalgo NR, Joigneau L, Pintado P, Rincón P, et al. Maternal and perinatal outcomes in pregnancy-associated melanoma: report of two cases and a systematic literature review. Eur J Obstet Gynecol Reprod Biol. 2017;214:131-9.
5. International Agency for Research on Cancer. Cancer today: data visualization tools for exploring the global cancer burden in 2022 [homepage]. Lyon: IARC; 2024 [cited 2024 Oct 23]. Available from: https://gco.iarc.who.int/today
6. Aitken JF, Elwood M, Baade PD, Youl P, English D. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer. 2010;126(2):450-8.
7. Brunssen A, Waldmann A, Eisemann N, Katalinic A. Impact of skin cancer screening and secondary prevention campaigns on skin cancer incidence and mortality: a systematic review. J Am Acad Dermatol. 2017;76(1):129-39.e10.
8. Breitbart EW, Waldmann A, Nolte S, Capellaro M, Greinert R, Volkmer B, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol. 2012;66(2):201-11.
9. Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ. Screening for reducing morbidity and mortality in malignant melanoma. Cochrane Database Syst Rev. 2019;6(6):CD012352.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Portuguese Journal of Family Medicine and General Practice

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors will assign to the RPMGF the sole right to publish and distribute the content of the manuscript specified in this declaration via physical, electronic, broadcasting or any other medium that may come into existence. They also grant the RPMGF the right to use and exploit this manuscript, in particular by assigning, selling or licensing its content. This permission is permanent and takes effect from the moment the manuscript is submitted, has the maximum duration allowed by applicable Portuguese or international law and is of worldwide scope. The authors further declare that this assignment is made free of charge. If the RPMGF informs the authors that it is not going to publish their manuscript, the exclusive assignment of rights ceases forthwith.
The authors authorise the RPMGF (or any entity it may appoint) to act on their behalf when it believes that copyright may have been infringed.